Results 21 to 30 of about 13,748 (197)

NTRK Fusions in 1113 Solid Tumors in a Single Institution

Diagnostics, 2022
Most NTRK fusions occur at very low frequencies in various common cancers. Recent recommendations on NTRK testing recommend immunohistochemistry (IHC) as the initial test for tumor types with a low frequency of NTRK fusions.
Heejin Bang, Mi-Sook Lee, Minjung Sung, Juyoung Choi, Sungbin An, Seok-Hyung Kim, Seung Eun Lee, Yoon-La Choi   +7 more
doaj   +1 more source

Identifying patients with NTRK fusion cancer [PDF]

Annals of Oncology, 2019
Due to the efficacy of tropomyosin receptor kinase (TRK) inhibitor therapy and the recent Food and Drug Administration approval of larotrectinib, it is now clinically important to accurately and efficiently identify patients with neurotrophic TRK (NTRK) fusion-driven cancer.
Solomon, J P, Benayed, R, Hechtman, J F, Ladanyi, M   +3 more
openaire   +3 more sources

A review of NTRK fusions in cancer

Annals of Medicine & Surgery, 2022
The family of the neurotrophic tropomyosin kinase receptors (NTRK or TRK) is a part of the transmembrane tyrosine kinases responsible for neuronal development. The members of this receptor family are TRKA, TRKB and TRKC and they are encoded by the genes NTRK1, NTRK2 and NTRK3.
Manea, Cristina Alexandra, Badiu, Dumitru Cristinel, Ploscaru, Ioan Cristian, Zgura, Anca, Bacinschi, Xenia, Smarandache, Catalin Gabriel, Serban, Dragos, Popescu, Cristian Gabriel, Grigorean, Valentin Titus, Botnarciuc, Vladimir   +9 more
openaire   +2 more sources

b-Jet Identification in the D0 Experiment [PDF]

, 2010
Algorithms distinguishing jets originating from b quarks from other jet flavors are important tools in the physics program of the D0 experiment at the Fermilab Tevatron p-pbar collider. This article describes the methods that have been used to identify b-
A. Alton, A. Askew, A. Bean, A. Boehnlein, A. Brandt, A. Bross, A. Chandra, A. Das, A. Dominguez, A. Dubey, A. Duperrin, A. Dyshkant, A. Evdokimov, A. Garcia-Bellido, A. Goussiou, A. Grohsjean, A. Haas, A. Harel, A. Jonckheere, A. Juste, A. Khanov, A. Kharchilava, A. Kumar, A. Kupco, A. Lobodenko, A. Melnitchouk, A. Meyer, A. Patwa, A. Quadt, A. Schwartzman, A. Sopczak, A. Sánchez-Hernández, A. Tanasijczuk, A. White, A.-F. Barfuss, A.A. Shchukin, A.K.A. Maciel, A.L. Lyon, A.P. Heinson, A.S. Ito, A.V. Ferapontov, A.V. Kozelov, A.V. Popov, Abachi, Abazov, Abazov, Abazov, Abe, Amsler, B. Abbott, B. Baldin, B. Calpas, B. Choudhary, B. Clément, B. Gómez, B. Hoeneisen, B. Penning, B. Quinn, B. Sanghi, B. Spurlock, B. Tiller, B. Tuchming, B. Zhou, B. Åsman, B.C.K. Casey, B.S. Acharya, Barlow, Bishop, Borisov, Buskulic, C. Avila, C. Belanger-Champagne, C. Hensel, C. Johnson, C. Royon, C. Schwanenberger, C. Tully, C. Xu, C.E. Gerber, C.L. McGivern, C.P. Buszello, D. Bloch, D. Boline, D. Brown, D. Buchholz, D. Chakraborty, D. Claes, D. Cutts, D. Denisov, D. Duggan, D. Edmunds, D. Gelé, D. Gerbaudo, D. Gillberg, D. Hedin, D. Jamin, D. Johnston, D. Karmanov, D. Khatidze, D. Lincoln, D. Mackin, D. Menezes, D. Onoprienko, D. Price, D. Schaile, D. Smirnov, D. Strom, D. Tsybychev, D. Vilanova, D. Wicke, D. Zieminska, D.A. Stoyanova, D.K. Cho, D.R. Wood, D.V. Bandurin, D’Hondt, E. Aguilo, E. Barberis, E. Camacho-Pérez, E. Carrera, E. De La Cruz-Burelo, E. Kajfasz, E. Nagy, E. Shabalina, E. Strauss, E.E. Boos, E.M. Gregores, E.W. Varnes, F. Badaud, F. Couderc, F. Déliot, F. Fiedler, F. Filthaut, F. Guo, F. Rizatdinova, Frühwirth, Frühwirth, G. Alkhazov, G. Alverson, G. Bernardi, G. Blazey, G. Borissov, G. Brooijmans, G. Chen, G. Davies, G. Facini, G. Ginther, G. Golovanov, G. Grenier, G. Gutierrez, G. Hesketh, G. Landsberg, G. Obrant, G. Safronov, G. Sajot, G. Savage, G. Watts, G. Weber, G.A. Alves, G.D. Alexeev, G.J. Otero y Garzón, G.R. Snow, G.S. Muanza, G.W. Wilson, H. Castilla-Valdez, H. Evans, H. Fox, H. Greenlee, H. Nilsen, H. Schellman, H. Severini, H. Yin, H.A. Neal, H.D. Wahl, H.D. Yoo, H.E. Fisk, H.J. Lubatti, H.S. Lee, H.T. Diehl, Hornik, I. Bertram, I. Hall, I. Heredia-De La Cruz, I. Iashvili, I. Katsanos, I. Razumov, I. Ripp-Baudot, I.A. Vasilyev, J. BackusMayes, J. Barreto, J. Cammin, J. Clutter, J. Ellison, J. Guo, J. Haley, J. Hays, J. Kraus, J. Kvita, J. Lellouch, J. Linnemann, J. Martínez-Ortega, J. Meyer, J. Orduna, J. Osta, J. Parsons, J. Piper, J. Qian, J. Sekaric, J. Snow, J. Stark, J. Strandberg, J. Warchol, J. Yu, J. Zhu, J.-F. Grivaz, J.A. Benitez, J.D. Hobbs, J.F. Bartlett, J.K. Lim, J.M. Hauptman, J.M. Kohli, J.P. Negret, K. Bloom, K. De, K. DeVaughan, K. Harder, K. Herner, K. Johns, K. Peters, K. Ranjan, K. Soustruznik, K. Yip, K.M. Chan, L. Bagby, L. Bellantoni, L. Duflot, L. Feligioni, L. Han, L. Li, L. Mendoza, L. Sawyer, L. Sonnenschein, L. Stutte, L. Uvarov, L. Zivkovic, L.S. Ancu, L.S. Vertogradov, L.V. Dudko, M. Abolins, M. Adams, M. Anastasoaie, M. Aoki, M. Arov, M. Begalli, M. Begel, M. Besançon, M. Buehler, M. Cooke, M. Corcoran, M. Demarteau, M. Diesburg, M. Eads, M. Fortner, M. Hohlfeld, M. Jaffré, M. Johnson, M. Kirsch, M. Lokajicek, M. Merkin, M. Mulhearn, M. Naimuddin, M. Narain, M. Owen, M. Padilla, M. Pangilinan, M. Perfilov, M. Prewitt, M. Rijssenbeek, M. Rominsky, M. Sosebee, M. Strauss, M. Takahashi, M. Titov, M. Verzocchi, M. Vesterinen, M. Wayne, M. Weber, M. Wetstein, M. Wobisch, M. Zielinski, M. Ćwiok, M.-A. Pleier, M.-C. Cousinou, M.-E. Pol, M.A. Carrasco-Lizarraga, M.A. Strang, M.D. Hildreth, M.H. Kirby, M.H.L.S. Wang, M.M. Meijer, M.P. Sanders, M.R.J. Williams, M.S. Rangel, M.W. Grünewald, Mangano, N. Huske, N. Khalatyan, N. Osman, N. Parashar, N. Parua, N. Varelas, N.K. Mondal, O. Atramentov, P. Baringer, P. Calfayan, P. Gay, P. Gutierrez, P. Haefner, P. Houben, P. Jonsson, P. Lebrun, P. Love, P. Neustroev, P. Polozov, P. Pétroff, P. Renkel, P. Rich, P. Rubinov, P. Skubic, P. Slattery, P. Svoisky, P. Verdier, P. Vint, P. Vokac, P.A. Kasper, P.C. Bhat, P.D. Grannis, P.G. Mercadante, P.K. Mal, P.L.M. Podesta-Lerma, P.M. Tuts, P.N. Ratoff, Ph. Gris, Q.Z. Li, R. Bernhard, R. Beuselinck, R. Brock, R. Demina, R. Hirosky, R. Illingworth, R. Jesik, R. Kehoe, R. Lipton, R. Luna-Garcia, R. Magaña-Villalba, R. McCarthy, R. Nayyar, R. Partridge, R. Piegaia, R. Ruchti, R. Schwienhorst, R. Ströhmer, R. Unalan, R. Van Kooten, R. Yamada, R.D. Schamberger, R.K. Shivpuri, S. Banerjee, S. Beale, S. Blessing, S. Burdin, S. Calvet, S. Chakrabarti, S. Chevalier-Théry, S. Choi, S. Cihangir, S. Desai, S. Dutt, S. Eno, S. Fuess, S. Greder, S. Grünendahl, S. Hagopian, S. Hossain, S. Jabeen, S. Jain, S. Kermiche, S. Lammers, S. Malik, S. Protopopescu, S. Robinson, S. Schlobohm, S. Snyder, S. Söldner-Rembold, S. Uvarov, S. Uzunyan, S. Yacoob, S. Zelitch, S.-J. Park, S.B. Beri, S.F. Novaes, S.J. de Jong, S.J. Wimpenny, S.K. Park, S.M. Lietti, S.P. Denisov, S.W. Cho, S.W. Youn, Sjöstrand, T. Adams, T. Bose, T. Christoudias, T. Dorland, T. Ferbel, T. Gadfort, T. Golling, T. Hebbeker, T. Hoang, T. Kurča, T. Moulik, T. Nunnemann, T. Scanlon, T. Schliephake, T. Yasuda, T. Zhao, T.A. Bolton, T.H. Burnet, T.R. Wyatt, U. Bassler, U. Heintz, V. Bhatnagar, V. Buescher, V. Bunichev, V. Gavrilov, V. Hynek, V. Parihar, V. Shary, V. Simak, V. Sirotenko, V. Stolin, V.A. Bezzubov, V.A. Kuzmin, V.D. Elvira, V.L. Malyshev, V.M. Abazov, V.M. Podstavkov, V.N. Evdokimov, V.V. Lipaev, V.V. Tokmenin, W. Fisher, W. Geist, W. Geng, W. Taylor, W.-C. Yang, W.E. Cooper, W.M. Lee, W.M. van Leeuwen, X.B. Bu, Y. Arnoud, Y. Enari, Y. Gershtein, Y. Hu, Y. Liu, Y. Maravin, Y. Peters, Y. Scheglov, Y. Xie, Y.A. Yatsunenko, Y.N. Kharzheev, Z. Hubacek, Z. Liu, Z. Ye, Z.D. Greenwood   +472 more
core   +6 more sources

Primary and Metastatic Melanoma With NTRK Fusions [PDF]

American Journal of Surgical Pathology, 2018
A number of oncogenic driver mutations have been identified in melanocytic nevi and melanoma, but translocations also play a role in tumorigenesis and provide potential therapeutic targets for malignant lesions. Various translocations, such as those involving the anaplastic lymphoma kinase (ALK), neurotrophic tropomyosin receptor kinase 1 (NTRK1), and ...
Cecilia, Lezcano, Alexander N, Shoushtari, Charlotte, Ariyan, Travis J, Hollmann, Klaus J, Busam   +4 more
openaire   +2 more sources

Genomic context of NTRK1/2/3 fusion-positive tumours from a large real-world population

npj Precision Oncology, 2021
Neurotrophic tropomyosin receptor kinase (NTRK) gene fusions are rare oncogenic drivers in solid tumours. This study aimed to interrogate a large real-world database of comprehensive genomic profiling data to describe the genomic landscape and prevalence
C. B. Westphalen, M. G. Krebs, C. Le Tourneau, E. S. Sokol, S. L. Maund, T. R. Wilson, D. X. Jin, J. Y. Newberg, D. Fabrizio, L. Veronese, M. Thomas, F. de Braud   +11 more
doaj   +1 more source

Potential novel therapy targets in neuroendocrine carcinomas of the breast [PDF]

, 2018
Neuroendocrine carcinoma (NEC) of the breast is a rare, special type of breast cancer, reportedly constituting 2% to 5% of all breast cancers. Although breast NEC does not have a specific targeted therapy, several new targeted therapies based on specific
Contreras, Elma, Florento, Elena, Gatalica, Zoran, Palazzo, Juan, Sanati, Souzan, Swensen, Jeffrey, Vranic, Semir, Xiu, Joanne   +7 more
core   +2 more sources

Identificación de genes de fusión NTRK. Experiencia en México

Gaceta Mexicana de Oncología, 2023
Objetivo: Evaluar la prevalencia de fusiones TRK en pacientes con cáncer en México. Material y métodos: En un estudio de tipo canasta, se determinó la presencia de genes de fusión NTRK, mediante inmunohistoquímica y secuenciación de nueva generación, en ...
Leticia Bornstein-Quevedo, Claudia Bautista-Wong, Zaira Mojica-González, Mario Gámez-Rosales, Katia Hop-García   +4 more
doaj   +1 more source

NTRK Somatic Fusions and Tumor Agnostic Treatment in Pediatric Cancers

Journal of Contemporary Medicine, 2022
Neurotrophic tyrosine receptor kinase (NTRK) gene rearrangements have been recently identified and developed as one of the biomarkers that have been utilized as new targets for cancer therapy.
Emel Ünal, Sonay İncesoy Özdemir, Ayça Yağmur Şimşek   +2 more
doaj   +1 more source

Review of precision cancer medicine: Evolution of the treatment paradigm. [PDF]

, 2020
In recent years, biotechnological breakthroughs have led to identification of complex and unique biologic features associated with carcinogenesis. Tumor and cell-free DNA profiling, immune markers, and proteomic and RNA analyses are used to identify ...
Fountzilas, Elena, Kurzrock, Razelle, Nikanjam, Mina, Tsimberidou, Apostolia M   +3 more
core   +1 more source